Drug intelligence / Profile preview

WB002

Development stage: Preclinical
Lead developer: Weben Pharma
Modality: Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules

Overview

WB002 is a preclinical-stage drug candidate being developed by Weben Pharma (Hangzhou Weiben Pharmaceutical Co. Ltd) for the treatment of leukemia. It is described as a derivative of Chinese natural products that has demonstrated anti-leukemia efficacy in preclinical studies. While the specific molecular target and mechanism of action have not been publicly disclosed by the developer, the compound represents Weben Pharma's strategy of leveraging natural product derivatives to create small-molecule therapeutics for oncology.

Targets

CEP250 (Centrosomal protein 250)

Beyond the preview

Go deeper on WB002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WB002.

Explore the full profile